Navigation Links
ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
Date:2/4/2011

CAMBRIDGE, Mass.,  Feb. 4, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today it has elected Anil Godhwani, a successful Silicon Valley entrepreneur, to its board of directors. ALS TDI is a 501(c)(3) "nonprofit biotechnology" organization with a mission to discover and develop treatments that effectively slow and stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease).

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"My mother was diagnosed with ALS last year and the disease is progressing rapidly. Shortly after her diagnosis, we met the amazing ALS TDI staff and their dedicated chairman Augie Nieto. I am honored to join the Board and work with my fellow directors to ensure that the Institute has the support it needs to continue to find ways to reduce the time and cost of drug development. I have no doubt that this organization will continue to change the way the world thinks about ALS," said Godhwani.

Godhwani is the co-founder of Simply Hired, an online job search engine based in Mountain View, Calif. The site has over 14 million visitors per month. Prior to Simply Hired Godhwani founded AtWeb, an online promotion and maintenance company, which he sold in 1998. Godhwani is also the co-founder of the India Community Center (ICC) in Milpitas, Calif., the largest Indo-American focused community organization in the country providing hundreds of programs annually to community members. Godhwani has helped raise over $15 million for ICC.

"Each member of our Board plays a unique role in helping us achieve our mission. As a successful entrepreneur and community philanthropist Anil will bring new experiences and fresh ideas. The executive team is looking forward to working with him, and the entire ALS community will benefit from having him take on a leadership role at ALS TDI," said the Institute's CEO & CSO, Dr. Steve Perrin.

Mr. Godhwani becomes the 12th member of the Board of Directors at ALS TDI. For information on the rest of the board, please visit http://www.als.net.  

About the ALS Therapy Development Institute

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, and operates the world's largest effort to pre-clinically validate potential therapeutics.  The world's first nonprofit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only nonprofit biotechnology company with more than 30 professional scientists.  In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development.  For more information, please visit us online at www.als.net.

Media Contact: Robert A. Goldstein, ALS TDI, rgoldstein@als.net, 617-441-7295


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
2. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
3. NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium
4. NeoStem Acquires Progenitor Cell Therapy
5. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
6. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
7. Reportlinker Adds Gene Therapy - technologies, markets and companies
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):